cethromycin

Cethromycin is a ketolide antibiotic derived from erythromycin A, classified as a macrolide. It exhibits broad-spectrum antibacterial activity against Gram-positive, Gram-negative, and atypical bacteria. Its primary mechanism of action involves binding to the 23S rRNA of the 50S subunit of bacterial ribosomes, thereby inhibiting protein synthesis by blocking the peptide exit tunnel and preventing ribosome assembly. Cethromycin has been investigated for use in mild-to-moderate community-acquired pneumonia (CAP), as well as for prophylaxis against inhalational anthrax, plague (Yersinia pestis), and tularemia (Francisella tularensis). It also shows activity against certain protozoa such as liver-stage malaria parasites via inhibition of their plant-like organelle. The drug was developed jointly by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences Holdings under the proposed trade name Restanza. Although it completed phase III trials for CAP and received orphan drug designations for several biothreat indications in the US, FDA approval was denied due to insufficient efficacy data[1][2][3][5][6][8].

Brand names

Restanza

Other names

CéthromycineCethromycinumCetromicina